uniQure N.V.

NASDAQ: QURE
$6.06
+$0.50 (+9.0%)
Closing Price on November 5, 2024

QURE Stock Chart and Intraday Price

QURE Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address PAASHEUVELWEG 25A, AMSTERDAM, NL
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 267.42M USD
Shares Outstanding 47,838,300
uniQure N.V., based in Amsterdam, specializes in pioneering gene therapies for rare and severe diseases. Its notable product, HEMGENIX, targets hemophilia B and has successfully completed a crucial Phase III trial. The company is also advancing treatments for Huntington’s disease, ALS, temporal lobe epilepsy, Fabry disease, Alzheimer’s, and Parkinson’s through various stages of clinical and preclinical development. Founded in 1998, uniQure is at the forefront of genetic medicine, aiming to transform the lives of patients with groundbreaking treatments.

QURE Articles

Tuesday's top analyst upgrades and downgrades included Ally Financial, Apple, Ardelyx, Block, DocuSign, D.R. Horton, Enovix, EOG Resources, Ford, Futu, Micron Technology, Novavax, PayPal, Pfizer and...
Thursday's top analyst upgrades and downgrades included Adobe, American Airlines, Coupa Software, Delta Air Lines, Host Hotels & Resorts, Nio, Novo Nordisk, Ralph Lauren, Roblox, SentinelOne and Walt...
Alliance Data, Cimarex Energy, Myriad Genetics and Nestle were among Tuesday afternoon's analyst upgrades and downgrades.
Friday's top analyst upgrades and downgrades included AT&T, Cisco Systems, Datadog, Dish Network, Energy Transfer, Pioneer Natural Resources, Splunk and Virgin Galactic.
Thursday's top analyst upgrades and downgrades included Carnival, Dow, Goldman Sachs, Micron Technology, Netflix, Oracle, Snap, Spotify and Twitter.
A new Stifel research report includes the firm's biotech stock picks for 2021. These five have the biggest upside to the posted price targets and are best suited for patient, aggressive growth...
Health care has been a top performer this year, and there is every reason to believe that performance will carry through into 2021. These are four of the highest-ranked health care ideas from the...
Tuesday's top analyst upgrades, downgrades and initiations included Alphabet, Amazon.com, Beyond Meat, CommScope, Enphase Energy, Nabors Industries, Netflix, Nike, Roku, Tesla, Uber Technologies and...
Here are eight secondary offerings that have been filed with a grand tally of about $3 billion combined.